MicroDose Technologies is a privately held premier drug delivery and specialty pharmaceuticals company. Founded in 1998, MicroDose is pioneering the use of proprietary drug delivery platforms for the pulmonary, oral and transdermal delivery of medications for improved efficacy and compliance. MicroDose's current focus is on the chronic disease states such as asthma, COPD, diabetes, hypertension and hyperlipidemia. MicroDose is a Delaware Corporation.

Drug Delivery Platforms

MicroDose has three core technology platforms. Each platform technology is supported by in-depth technical know-how and a portfolio of both issued and pending patents, and each can be applied across a broad range of disease states and therapeutic candidates. They are:

MicroDose utilizes its proprietary drug delivery technology platforms to create superior products in conjunction with pharmaceutical and biotechnology partners, and in the development of proprietary products utilizing generic drugs for its own use. MicroDose's lead product is an electronically controlled Dry Powder Inhaler (DPI). The MicroDose DPI is a handheld, low-cost, breath-activated device that utilizes piezo electronics to efficiently deliver a broad range of compounds. Such compounds include small or large molecule therapeutics for both local and systemic applications. The MicroDose inhaler achieves the holy grail in respiratory delivery, dose delivery that is inhalation flow rate independent. It achieves this is in all orientations, and independent of patient coordination. The device promises to be the first completely electronic DPI on the market and represents the next generation in inhaler technology both in performance and ease of use for patients (see Pulmonary Drug Delivery).

Our second technology is for solid oral dosage formats and enables the combination of two or more drugs into a single pill or capsule, but separated by a physical barrier. This physical barrier, between two fixed doses, allows for more rapid development timelines and lower regulatory requirements, at a fraction of the normal cost. This proprietary approach may enable patent extensions on blockbuster drugs whose patents are soon to expire. MicroDose has identified and is developing several combination products in the high growth areas of hypertension, hyperlipidemia and Type II diabetes (See Combination Oral Dosage).

MicroDose's needlefree systems approaches encompass battery operated, electromechanical approaches that control the non-invasive injection of micro-liter quantities of a drug in rapid pulses until the entire volume is delivered. Unlike systems using iontophoresis or electroporation, our systems will be able to deliver both small and large molecules. The system would be safe and simple to use, inexpensive, quiet, and would use drugs prepackaged specifically for a unit dose pack to eliminate cleaning and assure correct dosing (See Needlefree).

Please visit our User Agreement. Your continued use of this site will automatically constitute your agreement to be bound by all the terms and conditions of the User Agreement.

©2004 MicroDose Technologies, Inc.